Olivér Eipel

Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia

Katalin Csordás, Márta Hegyi, Olivér Eipel et al. · Anti-Cancer Drugs · 2012 · 70 citations

Hematological Malignancy, Csf Mtx, Oncology +14

Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma

Márta Hegyi, Ádám Arany, Ágnes F. Semsei et al. · Oncotarget · 2016 · 46 citations · Full text

Associations of novel genetic variations in the folate‐related and <i><scp>ARID</scp>5<scp>B</scp></i> genes with the pharmacokinetics and toxicity of high‐dose methotrexate in paediatric acute lymphoblastic leukaemia

Katalin Csordás, Orsolya Lautner‐Csorba, Ágnes F. Semsei et al. · British Journal of Haematology · 2014 · 41 citations · Full text

Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma

Márta Hegyi, Ágnes Gulácsi, E. Cságoly et al. · Journal of Cancer Research and Clinical Oncology · 2012 · 29 citations · Full text

Oncology, Methotrexate Pharmacokinetics, Metronomic Therapy +5

The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy

Olivér Eipel, Krisztína Németh, Dóra Török et al. · International Journal of Hematology · 2013 · 25 citations

Hematological Malignancy, Pediatric Hematology, Mixed-phenotype Acute Leukemia +6